AKESO EYECARE
AKESO Eyecare is a smart eyewear company that uses big data and internet of things technology to deliver intelligent eyewear and accompanying mobile applications for children and parents. Their products tracks and manages vision health of children and adolescents.
AKESO EYECARE
Industry:
Eyewear Personal Health Wearables
Founded:
2014-11-24
Address:
Beijing, Beijing, China
Country:
China
Website Url:
http://www.akeso.cn
Total Employee:
101+
Status:
Active
Contact:
400-7780-080
Total Funding:
33 M CNY
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Content Delivery Network LetsEncrypt SSL By Default IPv6 JsDelivr Nginx Ubuntu
Similar Organizations
Avisi Technologies
Avisi Technologies develops a nanotechnology-enabled defense against blindness from glaucoma.
Equip Health
Equip Health provides a virtual eating disorder treatment program designed to assist families recover from eating disorders at home.
Natural Cycles
Natural Cycles is a contraceptive app that spearheads the development of digital contraception.
Open Medical Innovation
Open Medical is a non-profit organization developing medical products for the patients and providers with urgent unmet medical needs.
Pair Eyewear
Pair Eyewear is an eyewear brand designed and made specifically for children.
Pair of Thieves
Pair of Thieves is a manufacturer and retailer of socks for men and children.
Tork
Tork offers professional hygiene products and services.
Valencell
Valencell develops performance biometric sensor technology and provides this patent-protected technology to wearables and hearables OEM's.
XEED
XEED manufactures wearables to help understand and treat Parkinson's disease.
Current Employees Featured
Founder
Investors List
Shouxi Yiliao Touzi
Shouxi Yiliao Touzi investment in Series B - AKESO Eyecare
Zhuopu Touzi
Zhuopu Touzi investment in Series A - AKESO Eyecare
Eyebright
Eyebright investment in Series A - AKESO Eyecare
Zhenliang Zichan
Zhenliang Zichan investment in Series A - AKESO Eyecare
Taihe Mengxiang
Taihe Mengxiang investment in Series A - AKESO Eyecare
Metagalaxy Capital Investment
Metagalaxy Capital Investment investment in Angel Round - AKESO Eyecare
Zhuopu Touzi
Zhuopu Touzi investment in Angel Round - AKESO Eyecare
Official Site Inspections
http://www.akeso.cn Semrush global rank: 13.04 M Semrush visits lastest month: 78
- Host name: 47.93.115.66
- IP address: 47.93.115.66
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "AKESO Eyecare"
Akeso, Inc | Home
Akeso, Inc. (HKEX Code: 9926. HK) is a biopharmaceutical company founded by a team of scientists with rich experience in global drug development and focuses on the unmet clinical needs worldwide in major diseases. The Company has …See details»
Akeso, Inc | Corporate Profile
In September 2024 ，Akeso’s first non-oncology drug and the fifth product in the commercial portfolio 伊喜宁 ® （PCSK9 Monoclonal antibody，Ebronucimab injection) has been approved by the NMPA in China ，for two indications of …See details»
Akeso, Inc | Home
Akeso,Inc. (HKEX Code: 9926.HK) is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class …See details»
康方生物 - Akeso, Inc | 公司简介
康方生物（港交所股票代码：9926.hk）成立于2012年，是一家集研究、开发、生产及商业化全球病人可负担的创新抗体新药于一体的生物制药公司，2020年4月24日正式在香港联合交易所有 …See details»
Akeso, Inc | Corporate Profile
Akeso, Inc. (9926.HK) is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to …See details»
Akeso Inc. 康方生物（9926.HK） - The Org
Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that …See details»
Akeso Biopharma | 领英 - 领英 (中国)
Akeso Biopharma | 在领英上有 2,052 位关注者。First in class and best in class therapeutic antibodies for patients worldwide. #9926.HK | Akeso (HKEX: 09926) is a commercial-stage …See details»
Akeso, Inc | 公司简介
自成立以来，公司建立了端对端全方位的药物开发平台（ACE平台），涵盖了全面一体化的药物发现和开发功能，包括靶点验证、抗体发现与开发、双特异抗体药物开发平台（Tetrabody平 …See details»
Akeso, Inc | Management Team - akesobio.com
Since its inception in 2012, Akeso has established the unique end-to-end Akeso Comprehensive Exploration Platform (ACE Platform). With a research and development innovation system …See details»
Akeso Biopharma - Crunchbase Company Profile & Funding
Akeso Biopharma closed its last funding round on Oct 13, 2024 from a Post-IPO Equity round. Who are Akeso Biopharma 's competitors? Alternatives and possible competitors to Akeso …See details»
Akeso Biopharma Co., Ltd. (中山康方生物医药有限公司) - 药物管 …
了解Akeso Biopharma Co., Ltd. (中山康方生物医药有限公司)公司的药物管线，治疗领域，技术平台，以及它的241项临床试验, 4篇新闻和21篇文献，疾病领域:肿瘤，免疫系统疾病，血液及淋 …See details»
Akeso, Inc | 管理团队
自2012年成立以来，公司打造了独有的康方全方位新药研究开发平台（ACE Platform），建立了以Tetrabody双特异性抗体开发技术、抗体偶联（ADC）技术、mRNA技术及细胞治疗技术为核 …See details»
Akeso Bay Area Science and Technology Park completed
Mar 28, 2024 The Akeso Bay Area Science and Technology Park was completed and put into operation in the eastern Cuiheng New District (Ma'an Island) on March 26. Akeso was founded …See details»
Akeso, Inc | Our Vision
Akeso Pharma AD Pharmaceuticals Contact Us Adverse Event Report Our vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation …See details»
Akeso, Inc | Akeso Inc. Announces Collaboration and License …
Dec 6, 2022 Akeso will retain development and commercialization rights for the rest of the world including China. In addition, Dr. Michelle Xia will be appointed as one member of the board of …See details»
Akeso Announced the Inclusion in China's National ... - Morningstar
Nov 28, 2024 Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab. PR Newswire. HONG KONG, Nov. 27, 2024. HONG KONG, …See details»
Akeso, Inc | Management Team - 113.190.248.146:8098
Akeso Pharma AD Pharmaceuticals Contact Us Adverse Event Report Founding Management Team. Michelle Xia, Ph.D. Founder, Chairwoman, CEO, and President. Since its …See details»
Collaborations - Akeso, Inc
To accelerate the commercialization of our marketed products, we have established a joint venture company, CTTQ-Akeso, with Chia Tai Tianqing (CTTQ), a principal subsidiary of Sino …See details»
Akeso, Inc | Akeso News
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid …See details»
康方生物 - Akeso, Inc | 韩宝惠教授专访：卡度尼利有望破局免疫耐 …
1 day ago 2024年10月，亚洲肺癌大会（aclc）在香港隆重举办，上海市胸科医院韩宝惠教授对双特异性抗体卡度尼利单抗的一项重磅研究进行了口头汇报（oa01.09），本项研究是卡度尼利 …See details»